J&J's Bid For Crucell Hits Speed Bump With Shipment Suspension At Korean Vaccine Plant
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson's acquisition offer for Crucell appears to be on track despite news that the Dutch biotech firm suspended all shipments of hepatitis B vaccine Hepavax-Gene and childhood pediatric vaccine Quinvaxem due to issues at its Korean unit Berna Biotech Korea.
You may also be interested in...
Eli Lilly, J&J, Novartis: Emerging Markets Earnings Roundup (Part 1 of 2)
Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets.
Eli Lilly, J&J, Novartis: Emerging Markets Earnings Roundup (Part 1 of 2)
Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets.
J&J Obtains Approval By Crucell's Boards For Proposed Purchase
Acquisition would add vaccines to J&J's diverse empire, and make it the sixth-largest player in that space.